At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 215 enrolled
Drug / intervention
Betrixaban +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluation of the Factor Xa Inhibitor, PRT054021, Against Enoxaparin in a Randomized Trial for the Prevention of Venous Thromboembolic Events After Unilateral Total Knee Replacement (EXPERT)
In Brief
A Phase 2 clinical trial evaluating Betrixaban and Enoxaparin for Thromboembolism. Completed, enrolled 215 participants across 1 site.
Detailed Summary
Randomized study of PRT054021 40 mg and 15 mg bid vs. enoxaparin 30 mg q12h for the prophylaxis of venous thromboembolic events after unilateral knee replacement surgery.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsThromboembolism
CountriesCanada
Collaborators--
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMay 2006
First PostedSep 2006
Primary CompletionJan 2007
Study CompletionFeb 2007
TodayJul 2026
First PostedSep 13, 2006
Enrollment StartMay 1, 2006
Primary CompletionJan 1, 2007
Study CompletionFeb 1, 2007
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 19.8 years ago
Interventions
Betrixabandrug
Capsule
Enoxaparindrug
Administered subcutaneously